
Strides Pharma Science Limited has informed the Exchange regarding a press release dated August 02, 2023, titled "Strides reports highest ever EBITDA, INR 1,686m in Q1FY24".
Filed with NSE ·

Strides Pharma Science Limited has informed the Exchange regarding a press release dated August 02, 2023, titled "Strides reports highest ever EBITDA, INR 1,686m in Q1FY24".
6ix hasn’t read this filing yet.
Strides Pharma Science Ltd on 6ix
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science